ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO687

Outcomes of Immunosuppressive Therapy in Lupus Nephritis

Session Information

Category: Glomerular Diseases

  • 1303 Glomerular Diseases: Clinical‚ Outcomes‚ and Trials


  • Tan Lim, Pamela Ong, National Kidney and Transplant Institute, Quezon City, National Capital Region, Philippines

Lupus Nephritis (LN) is one of the severe manifestations of Systemic Lupus Erythematosus (SLE). Renal involvement is seen in about >50% of the patients which caused significant morbidity. Over the past decades, the survival rate of patients with LN has improved dramatically because of improvement in the classification of patients, improvement in diagnosis, more intensive treatment with the use of immunosuppressive/cytotoxic agents, high dose corticosteroid pulse therapy, and advances in the treatment of hypertension, infections and renal failure.


Biopsy proven LN patients, diagnosed from January 2015 to December 2019, and started on immunosuppressive therapy were included. The demographic and clinical characteristics were retrieved from electronic medical records. Laboratory results at baseline, at initiation of treatment, and at time of remission and flare were assessed.


Fifty-five biopsy proven LN patients were included. Median age was 27 years at time of biopsy and majority were female (89.09%). Thirty one (56.36%) patients had Class IV LN; the median lupus activity score was 4 (ranging from 0-12), and chronicity score was 2 (ranging from 0-12). Complete remission was observed in 16 (29.09%) patients and partial remission was noted in 31 (56.36%) patients. There was no response in three patients, ESRD in five patients and no deaths. The time to remission is at 6 months on the average and the median time to renal flare was 18 months. The risk of renal flares increases by 2% for every one month increase in the delay between diagnosis and treatment.


Among patients diagnosed with LN, treatment with induction therapy followed by maintenance therapy ensured good efficacy. The occurrence of renal flare after initiation of treatment was 18 months. Early response to treatment on diagnosis may lessen risk of renal flares.